A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis

被引：7

作者：

Roostaeyan, Omid ^{[1
]}

Kivelevitch, Dario ^{[2
]}

Menter, Alan ^{[2
]}

机构：

[1] Univ Oklahoma, Coll Med, Oklahoma City, OK 73019 USA

[2] Baylor Scott & White, Div Dermatol, Dallas, TX 75246 USA

来源：

IMMUNOTHERAPY | 2017年 / 9卷 / 12期

关键词：

anti-IL-17; biologics; brodalumab; efficacy; IL-17; monoclonal antibodies; psoriasis; safety; therapeutics; OPEN-LABEL EXTENSION; INTERLEUKIN-17; RECEPTOR; NEUTROPHIL RECRUITMENT; TNF-ALPHA; ANTI-INTERLEUKIN-17-RECEPTOR ANTIBODY; MONOCLONAL-ANTIBODY; JOINT INFLAMMATION; SKIN INFLAMMATION; CLINICAL-RESPONSE; CELL-POPULATION;

D O I：

10.2217/imt-2017-0077

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Psoriasis is a chronic immune-mediated skin disorder affecting approximately 2-3% of the worldwide population. Recent advances in our understanding of the immunopathogenesis of psoriasis have resulted in novel therapeutic agents. IL-17, a pro-inflammatory cytokine, plays a pivotal role in psoriasis. Therapeutic agents targeting this cytokine have shown clinical effectiveness in the treatment of moderate-to-severe plaque psoriasis. Brodalumab, a human antibody against IL-17 receptor A, has been approved by the US FDA in February 2017, by the Japanese Pharmaceuticals and Medical Devices Agency in July 2016 and by the EMA in July 2017 for the treatment of moderate-to-severe psoriasis. This article reviews the published data relating to brodalumab for the treatment of moderate-to-severe plaque psoriasis.

引用

页码：963 / 978

页数：16

共 50 条

[31] Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
Jo Lambert
Jes Birger Hansen
Anne Sohrt
Luis Puig
Dermatology and Therapy, 2021, 11 : 1265 - 1275
[32] Brodalumab provides rapid improvement in psoriasis-related itch and pain in patients with moderate-to-severe plaque psoriasis
Lebwohl, M.
Reich, K.
Paul, C.
Rosen, M.
Hansen, K.
BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 75 - 75
[33] EFFICACY OF BRODALUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: A NETWORK META-ANALYSIS
Xue, W.
Barbeau, M.
Khoudigian-Sinani, S.
Gray, E.
Saharia, P.
Frieder, D.
VALUE IN HEALTH, 2018, 21 : S239 - S239
[34] COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
Solakidi, A.
Tzanetakos, C.
Kontodimas, S.
Kourlaba, G.
VALUE IN HEALTH, 2018, 21 : S428 - S428
[35] Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature
Kory P. Schrom
Avi Bitterman
Neil J. Korman
Current Dermatology Reports, 2019, 8 : 6 - 13
[36] Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature
Schrom, Kory P.
Bitterman, Avi
Korman, Neil J.
CURRENT DERMATOLOGY REPORTS, 2019, 8 (01) : 6 - 13
[37] Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis
Wong, Ian T. Y.
Shojania, Kam
Dutz, Jan
Tsao, Nicole W.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 153 - 166
[38] Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
Light, Jeremy G.
Su, Jennifer J.
Feldman, Steven R.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2021, 14 : 55 - 63
[39] Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis
Scanlon, James V.
Exter, Benjamin P.
Steinberg, Michael
Jarvis, Courtney I.
ANNALS OF PHARMACOTHERAPY, 2009, 43 (09) : 1456 - 1465
[40] Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis
Leman, J.
Burden, A. D.
BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : 12 - 20

← 1 2 3 4 5 →